Blueprint Medicines Corporation (NASDAQ: BPMC) stock closed at 69.64 per share at the end of the most recent trading day (a 1.69% change compared to the prior day closing price) with a volume of 762.75K shares and market capitalization of 4.23B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Blueprint Medicines Corporation CEO is Jeffrey W. Albers.

The one-year performance of Blueprint Medicines Corporation stock is 43.29%, while year-to-date (YTD) performance is 58.96%. BPMC stock has a five-year performance of 21.39%. Its 52-week range is between 37.82 and 69.985, which gives BPMC stock a 52-week price range ratio of 98.93%

Blueprint Medicines Corporation currently has a PE ratio of -3.90, a price-to-book (PB) ratio of 4.38, a price-to-sale (PS) ratio of 16.57, a price to cashflow ratio of 16.20, a PEG ratio of -0.11, a ROA of -52.96%, a ROC of -64.78% and a ROE of -84.58%. The company’s profit margin is 41.08%, its EBITDA margin is -256.20%, and its revenue ttm is $165.26 Million , which makes it $2.76 revenue per share.

Of the last four earnings reports from Blueprint Medicines Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-2.39 for the next earnings report. Blueprint Medicines Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Blueprint Medicines Corporation is Moderate Buy (1.65), with a target price of $77.5, which is +11.29% compared to the current price. The earnings rating for Blueprint Medicines Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Blueprint Medicines Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Blueprint Medicines Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 7.98, ATR14 : 2.72, CCI20 : 122.16, Chaikin Money Flow : 0.02, MACD : 4.21, Money Flow Index : 76.05, ROC : 18.33, RSI : 73.15, STOCH (14,3) : 87.39, STOCH RSI : 0.79, UO : 61.56, Williams %R : -12.61), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Blueprint Medicines Corporation in the last 12-months were: Albers Jeffrey (Sold 0 shares of value $-454 000 ), Albers Jeffrey (Sold 60 000 shares of value $3 091 159 ), Ariel Hurley (Sold 1 126 shares of value $51 435 ), Becker Hewes (Sold 1 514 shares of value $69 174 ), Carter Percy (Sold 3 068 shares of value $154 872 ), Carter Percy H. (Sold 2 307 shares of value $120 102 ), Christina Rossi (Sold 3 059 shares of value $139 715 ), Christopher K. Murray (Sold 1 875 shares of value $85 641 ), Debra Durso-Bumpus (Sold 3 158 shares of value $144 248 ), Fouad Namouni (Sold 1 948 shares of value $88 977 ), Haviland Kate (Sold 6 640 shares of value $303 354 ), Hewes L. Becker (Sold 1 404 shares of value $73 078 ), Hurley Ariel (Sold 1 126 shares of value $51 435 ), Jeffrey W. Albers (Option Excercise at a value of $150 100), Jeffrey W. Albers (Sold 29 793 shares of value $1 449 073 ), Kathryn Haviland (Sold 6 640 shares of value $303 354 ), L. Becker Hewes (Sold 2 918 shares of value $142 253 ), Landsittel Michael (Sold 3 007 shares of value $137 361 ), Lee Philina (Sold 1 676 shares of value $76 555 ), Mccain Tracey (Sold 3 322 shares of value $151 743 ), Michael Landsittel (Sold 3 007 shares of value $137 361 ), Murray Christopher (Sold 2 475 shares of value $119 481 ), Namouni Fouad (Sold 5 717 shares of value $270 115 ), Percy H. Carter (Sold 761 shares of value $34 769 ), Philina Lee (Sold 1 676 shares of value $76 555 ), Rossi Christina (Sold 3 059 shares of value $139 715 ), Tracey McCain (Sold 3 322 shares of value $151 743 )